New Data from Ongoing CDC Study Presented at IDWeek 2013- Confirms Tru-D SmartUVC’s Accuracy in Calculating Pathogen-Lethal UV Dose

Posted by Tru-D SmartUVC 10.02.13

At IDWeek 2013™, new research from an ongoing $2 million study funded by the Centers for Disease Control’s Epicenter Program at Duke University and the University of North Carolina will be presented in the poster abstract session Role of the Healthcare Environment in HAIs on Oct. 5.

During the 11-month study, titled “Inter-hospital Variation in Time Required for Hospital Room Ultraviolet Irradiation” (Deverick H. Anderson, M.D., MPH et al., 2013), nearly 10,000 patient rooms were disinfected using Tru-D. The research shows that UV-C disinfection devices without patented intuitive technology like Tru-D’s Sensor360™ are likely to under- or overestimate the time necessary to adequately disinfect patient rooms. The data also showed that disinfection times varied depending on room variables and the type of organism targeted. Earlier this year, the CDC released additional research from the ongoing study confirming Tru-D’s effectiveness in killing harmful pathogens like Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp.

Tru-D, which works by generating UV-C light energy that modifies the DNA structure of an infectious cell, is the only portable UV-C disinfection system on the market with Sensor360 technology. Sensor360 automatically calculates the time needed to react to room variables – such as size, geometry, surface reflectivity and the amount and location of equipment in the room – and effectively delivers a lethal UV-C dose from a single, central location in the room.

A combined meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association and the Pediatric Infectious Diseases Society taking place Oct. 2 through 6 in San Francisco, Calif., IDWeek is a recognized forum for peer-reviewed presentations of new research and clinical analysis in infectious disease and HIV. Leadership from Lumalier Corporation, makers of Tru-D, will be in attendance and available to discuss the critical need for UV disinfection technology in health care settings, along with infectious disease, epidemiology and prevention professionals, at the meeting’s exhibit hall Oct. 3 through 5.

“We consistently hear from disease prevention professionals that the use of Tru-D in their hospital has significantly reduced health care-associated infections,” said Chuck Dunn, president of Lumalier Corporation. “You can only get consistent outcomes with Tru-D’s intuitive SmartUVC technology, and that’s one specific reason only Tru-D has been validated by more than 10 independent studies in important journals trusted by experts.”

Tru-D allows hospitals to confidently clean and disinfect their patient environments, killing pathogens such as C. diff., Methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE). Studies have shown that traditional disinfection methods are only 50 percent effective, leaving pathogens behind. After a hospital staff member cleans the room using traditional methods, Tru-D is rolled into the room to “finish the job.” The system can disinfect an entire room – including shadowed spaces – from one location, eliminating the need to move it to multiple places in the room. Its patented Sensor360 technology analyzes the unique variables of the room and floods the space (both line-of-site and shadowed spaces) with the proper dose of UV light energy.

Tru-D SmartUVC is the device of choice for nearly all of the existing independent research on UV disinfection technology. More than 100 TRU-Ds have been deployed to disinfect hospitals across the U.S., Canada and Europe, including the Walter Reed Army Medical Center in Washington, D.C., Anne Arundel Medical Center in Baltimore, Md., Lehigh Valley Health Network in Allentown, Pa., and Vancouver General Hospital in Vancouver, British Columbia.

For information and links to independent studies on Tru-D, click here.

About IDWeek 2013™

IDWeek 2013TM is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2013 takes place Oct. 2 through 6 at the Moscone Center in San Francisco, Calif. For more information, visit www.idweek.org.

– See more at: http://www.tru-d.com/news/new-data-from-ongoing-cdc-study-presented-at-idweek-2013–confirms-tru-d-smartuvcs-accuracy-in-calculating-pathogen-lethal-uv-dose/#sthash.DOweXcrd.dpuf

Posted 10.02.13
  • Share

Never miss the latest in UV news.
Subscribe to UVC360 today.

Sign Up »